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Abstract 
The Plasmodium vivax Duffy Binding Protein (DBP) is the ligand in the major 
pathway for P. vivax invasion of human reticulocytes, making it an appealing 
vaccine candidate.  Region II of DBP (DBP-RII) is the minimal portion of the 
ligand that mediates recognition of the Duffy Antigen Receptor for Chemokines 
(DARC receptor) on the reticulocyte surface and constitutes the primary vaccine 
target.  Analysis of natural variation in the coding sequences of DBP-RII revealed 
signature evidence for selective pressure driving variation in the residues of the 
putative receptor-binding site. We hypothesize that anti-DBP immunity in P. vivax 
infections is strain-specific and hindered by polymorphic residues altering 
sensitivity to immune antibody inhibition.  To comprehend the human IgG 
response following P. vivax infections we investigated the specificity of IgG in 
Pursat Province, Western Cambodia.  Using ELISAs, we quantified the antibody 
titer against five variant alleles of DBP-RII. We also sequenced the DBP-RII of 
the field isolates to determine their relationship to the variant alleles used in the 
ELISAs.  When correlating the IgG titer between the DBP variants a strain-
specific immune response was observed in patients with a high antibody titer to 
DBP-RII_AH as compared to the other variants.  This was different from the 
correlation of high antibody titers between DBP-RII_P and DBP-RII_7.18 
(ρ=0.88, p-value<0.0001) and DBP-RII_P and DBP-RII_O (ρ=0.87, p-
  vii 
value<0.0001).  There appeared to be little correlation between specific 
polymorphic residues and IgG titer.  Understanding the immune response to the 
polymorphisms within PvDBP will allow further identification of epitopes to enable 
the production of a more effective P. vivax vaccine. 
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Literature Review 
1.0 Malaria Worldwide 
Malaria is one of the most widespread vector-borne illnesses to plague the 
world.   According to a report presented by the WHO that surveyed over 106 
malaria endemic countries, in 2009 there were an estimated 225 million cases of 
malaria with an estimated 800,000 fatalities in 2010 (WHO, 2010a).   Malaria is 
caused by the Plasmodium parasite being transmitted through the saliva of.  The 
five human Plasmodium parasites require both mosquito and a human host to 
survive.  Although control and elimination of malaria infections has been 
achieved in numerous countries, plans for worldwide eradication of the disease 
has been met with multiple obstacles.  Increasing drug-resistance among 
parasites has made it difficult for healthcare providers to effectively treat 
infections and has been increasing the cost of treatment in already impoverished 
regions.  Also, due to the parasites ability to evade the human host’s immune 
system, production of a malaria vaccine that addresses all variants parasites has 
eluded researchers.  This has results in current efforts to minimize infections 
through vector control and controlling drug-resistance as much as possible.  
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2.0 Malaria Life Cycle 
 The five species of malaria found to infect humans are Plasmodium 
falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and 
Plasmodium knowlesi (Vythilingam et al., 2006).  Although Plasmodium 
falciparum is known to cause the most severe disease and is highly prevalent in 
Africa, Plasmodium vivax (P. vivax), causing a milder form of malaria in many 
cases, is thought to account for nearly 56% of non-African malarial infections 
worldwide (K. Mendis, Sina, Marchesini, & Carter, 2001).  P. vivax has a 48 hour 
life cycle in humans (Figure 1), starting from inoculation of sporozoites to 
gametocyte production (Karunaweera, Grau, Gamage, Carter, & K. N. Mendis, 
1992).  P. vivax parasites undergo liver stage and an erythrocytic stage in 
humans.  During the liver stage sporozoites infect hepatocytes and produce 
schizonts, which rupture the cell and release merozoites.  In P. vivax, merozoites 
are carried to the circulatory system where they invade reticulocytes and begin 
the erythrocytic stage.  During this stage schizonts mature to form trophozoties, 
which will either mature into gametocytes and be transmitted to Anopheles 
mosquitoes during a blood meal, or will mature into schizonts, rupture the cell, 
and merozoites infect nearby reticulocytes (T. J. Hadley, Klotz, & Louis H. Miller, 
1986).  Since human adult blood contains approximately 1% reticulocytes, the 
parasitemia for P. vivax infections is usually much lower than that of P. 
falciparum (T. J. Hadley, Klotz, & Louis H. Miller, 1986) .  
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Figure 1: Plasmodium Life Cycle.  The general life cycle for human Plasmodium species, as 
provided by Hadley et al.  The erythrocytic cycle (boxed), including merozoite invasion, is the 
focus of this study. 
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3.0 P. vivax Invasion 
 3.1 Invasion Pathway.  The only known pathway for P.vivax invasion is via 
erythrocyte binding by the Duffy Bind Protein (DBP) (Figure 2).  DBP is housed in 
the microneme of merozoites and released to the parasite surface during 
invasion (M Aikawa, L H Miller, Johnson, & Rabbege, 1978; Ladda, Masamichi 
Aikawa, & Sprinz, 1969).  The merozoite attaches to the host reticulocyte and 
undergoes reorientation to position the apical end on the erythrocyte, deforming 
the erythrocyte (M Aikawa et al., 1978; Ladda et al., 1969).  At this point, DBP is 
released from the microneme and facilitates the engulfing of the parasite into the 
parasitophorous vacuole (VanBuskirk, Sevova, & John H Adams, 2004) .   
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Figure 2: P. vivax Merozoite Invasion.  Image provided in Beeson et al.  (A) The P. vivax 
merozoite attaches to the reticulocyte surface and undergoes reorientation.  DBP is released tot 
eh surface of the merozoite and facilitates parasite invasion.  (B)The interaction between the DBP 
ligand region II and the DARC blood group antigen on the surface of the erythrocyte allow the 
parasite to invade (J.G. Beeson & Crabb, 2007). 
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DBP is a large, seven region transmembrane protein, with region II and 
region IV being the most cystine-rich, meaning their function depends on proper 
conformations (VanBuskirk, Sevova, & John H Adams, 2004).  The Duffy binding 
like (DBL) domain binds to the Duffy antigen/receptor for chemokines (DARC) on 
the surface of the Duffy blood group antigen on the host cell and allows the 
merozoite to be engulfed in the parasitophorous vacuole, where it progresses to 
a trophozoite (Hadley, Klotz, & Louis H. Miller, 1986; Grimberg et al., 2007).  As 
the preferred method of invasion, it is generally accepted that only person with 
the Duffy blood group antigen are able to contract P. vivax infections (T. J. 
Hadley, Klotz, & Louis H. Miller, 1986; Horuk et al., 1993).   
 3.2 Immune System Complications.  Since the DBP/DARC interaction is 
the most important pathway for P. vivax invasion, DBP is presented as a viable 
vaccine target.  Removal of the Duffy blood group antigens by treating the 
erythrocyte with chymotryspin prohibits P. vivax invasion (A. P. Singh et al., 
2005) .  However, a DBP vaccine has been difficult to procure for two reasons.  
First, DBP is released very quickly during invasion, leaving is small window of 
opportunity for antibody production (VanBuskirk, Sevova, & John H Adams, 
2004).  Second, antibodies created to DBP don’t confer lasting immunity to P. 
vivax infections due the multitude of polymorphic residues found throughout 
DBPII, contains the binding site for invasion (C.E. Chitnis & L.H. Miller, 1994; 
Ranjan & C.E. Chitnis, 1999).  The polymorphic residues create variant strains of 
P. vivax due to pressure from the immune system.  These residues also tend to 
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be located near epitopes essential for DBP binding to erythrocytes and can 
misdirect the host’s immune system (Chootong et al., 2010; VanBuskirk, Sevova, 
& John H Adams, 2004).  Antibodies to variant strains are made to these 
polymorphic residues instead of the conserved residues essential for erythrocyte 
binding (Chootong et al., 2010; VanBuskirk, Sevova, & J. H. Adams, 2004; K. 
Mendis et al., 2001).  This may limit the cross-reactivity of antibodies between 
variants.   
3.3 Vaccine Development Complications.  One of the vaccine strategies 
that has emerged to overcome these obstacles; a combination vaccine that 
includes highly immunogenic and cross-reactive DBP variants (M Arévalo-
Herrera & S Herrera, 2001; Sócrates Herrera, Corradin, & Myriam Arévalo-
Herrera, 2007).  However, the immune response to variant DBP alleles is not 
fully understood; therefore it is unclear which DBP allele is the most 
immunogenic and can provide the most cross-reactive immune response 
possible.  Also, antibodies to DBP provide only short-term immunity to vivax 
infections (K. Mendis et al., 2001).  Furthermore, the number of DBP variants and 
their distribution from region to region is also unknown.  It’s unknown if a 
combination vaccine would need to be specialized by region or modified from 
year to year.         
Along with multiple variant alleles of DBP, P. vivax exposure varies across 
the world.  For example, inhabitants of Papua New Guinea (PNG), a highly 
endemic region, are constantly exposed to P. vivax and have been known to 
8 
 
acquire some form of immunity or asymptomatic infection as they age (Cattani et 
al., 1986; Xainli et al., 2002).  By contrast, inhabitants of a low endemic region, 
for example Cambodia, are less likely to have constant exposure to P. vivax; 
therefore, would have very little immunity and would become ill from a P. vivax 
infection (Luxemburger et al., 1997; Luxemburger et al., 1996).  It is unclear if a 
combination vaccine would meet the needs of both types of regions.   
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4.0 Cambodian Population 
Cambodia is a small country in Mekong subregion of Southeast Asia, 
adjacent to Thailand, Laos, and Vietnam.  The country is comprised of 24 
provinces.  According to the last census taken in 2008, Cambodia had 
13,388,910 inhabitants (NIS, 2008).  In Cambodia, Dengue fever, tuberculosis, 
HIV, intestinal parasitic infections, and malaria are the most endemic diseases.  
For malaria, most cases are centralized around Cambodia’s dense forest 
regions, along the Thai and Vietnam borders (Cui et al., 2011).  The two most 
prevalent species of malaria here are P. falciparum and P. vivax, constituting 
over 80,000 malaria cases in 2008 (Cui et al., 2011; Dysoley et al., 2008).   
4.1 The Forests of Cambodia.  The forests of Cambodia, like many areas 
in Southeast Asia, constitute a low, seasonally transmission P. vivax infections 
(Luxemburger et al., 1997; Dysoley et al., 2008).  When non-forest inhabitants go 
into the forest to work during the rainy season, from April to December, they may 
return to their homes with a P. vivax infection.  Medications are readily available 
over the counter and are relatively inexpensive; however, due to unsupervised 
medication regiments, this process has been leading to drug-resistance.  Also, P. 
vivax can lie dormant for several months, further complicating the malaria 
situation (Adak, Sharma, & Orlov, 1998).   
 4.2  Pursat Province.  Pursat, a province in western Cambodia located 
along the Thai border, is a typical example of a malaria endemic province.  
Although there are five additional districts in Pursat, Veal Vang, along the Thai 
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border, is covered with mountainous forests (Figure 3).   The Kravanh district has 
some forest in the west, but is mostly known as the forest fringe.  Karkor, Bakan, 
and Kandieng are all districts that border Cambodia’s Great Lake, Tonle Sap 
Lake.  Sempov Meas  contains the district capital, also known as Pursat.  In 
2008, Pursat province had a population of 397,161 (NIS, 2008).  Although the 
largest district by land mass, Veal Vang contained 3.2% of the province’s 
population with only 13,052 people (NIS, 2008).  The people of this region are 
highly migratory, making it difficult to track malaria infections among them.  Also, 
due to the dense terrain, inhabitants of the forest region are difficult to reach.     
11 
 
 
 
Figure 3: Map of Pursat Province in Western Cambodia.  The district borders of Pursat province 
as of the 2008 census.  District names, provided in Khmer have been translated into English.  
TheVeal Vang district on the western border of Pursat is along the Thai/Cambodia border, while 
the north eastern border is along the Tonle Sap Lake.   
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 Although Veal Vang is the least populated district in Pursat province, 
approximately 51.2% of the population makes their living on work done there; 
including market-oriented and subsistence agriculture, mining, and lumber.  
205,478 men and women, ranging from age 5 to 97 make their living in the forest 
(NIS, 2008).  The forest is also the main breeding ground for Aneopholes dirus, 
the main malaria vector in the Mekong region (Phimpraphi et al., 2008).  In 
general, workers arrive in the forest free of malaria infections, but return home 
infected; similar to the pattern of infection in the forest region of Thailand, along 
the Myanmar border (Dysoley et al., 2008).  Also, although it hasn’t been as well 
documented as the Karen communities in Thailand, it is believed that year round 
inhabitants of Veal Vang show signs of acquired immunity with age due to a 
more constant exposure to malaria.   
4.3 Pursat Collaboration.  Dr. Rick Fairhurst, M.D., Ph.D. of the NIH/NIAID 
is conducting a study in Pursat province to better understand P. vivax infection in 
the low endemic regions.   The five year study, beginning in 2008, took place at 
the Pursat Provincial Clinic in the capital of Pursat where data was collected from 
April to December (the perceived rainy season).  Individuals suspected of malaria 
infections either came to the clinic or were collected along the Hwy 5, the main 
road leading to Veal Vang.  All malaria screenings took place at the Pursat 
Provincial Clinic and treatment was provided regardless of enrollment in the 
study.  Only volunteers that satisfied the inclusion criteria and provided informed 
consent were enrolled in the study and asked to donate no more than 24ml of 
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blood.  In 2008, enrolled volunteers ranged from 2-75 years of age, with 150 
males and 86 females (Table 1).  Through collaboration with the Pursat 
Collection Study we hope to further investigate the distribution and immune 
response of DBP variants in a seasonally endemic region.  The purpose of this 
study is to determine which polymorphic allele of the DBL domain is responsible 
for the largest burden of disease in the non-forest districts of Pursat, Cambodia, 
and to determine if specific polymorphic alleles are responsible for the burden of 
disease.  We hypothesize that the prominent DBP polymorphisms will vary by 
infection; thereby effecting the immune response throughout Pursat province. 
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Table 1: Study Population in Pursat, Cambodia.   
 
*Forest districts in Pursat involved with malaria transmission.  Inhabitants from other districts travel to the 
forest districts for work and return to their home districts with malaria. The infection rate is the number of 
number of infected patients in the study compared to the districts population and does not reflect incidence 
cases in each district. 
 
 
 
  
 
Study Population in Pursat, Cambodia 
 
  
Pursat Collection 
Study Pursat Census 
Infection Rate 
(per 1000) 
  
  
Male Female Male Female Male Female 
Bakan 
              
  13-18 years - 1 (100) 10944(50.9) 10574(49.1) 0.00 0.09 
  19-30 years 4 (80) 1 (20) 13988(49.6) 14218(50.4) 0.29 0.07 
  31-50 years 2 (33.3) 4 (66.7) 10612(46.4) 12268(53.6) 0.19 0.33 
  51 and older - 1 (100) 5602  (40.9) 8090  (59.1) 0.00 0.12 
Kandieng 
          
  19-30 years 3 (100) - 6330  (48.7) 6674  (51.3) 0.47 0.00 
  31-50 years 5 (83.3) 1 (16.7) 5203  (45.8) 6161  (54.2) 0.96 0.16 
Krakor 
          
  2-12 years 7 (77.8) 2 (22.2) 11070 (51) 10650 (49) 0.63 0.19 
  13-18 years 8 (100) - 6904  (50.9) 6670  (49.1) 1.16 0.00 
  19-30 years 27 (96.4) 1 (3.6) 9058  (50.3) 8955  (49.7) 2.98 0.11 
  31-50 years 5 (62.5) 3 (37.5) 7461  (45.7) 8854  (54.3) 0.67 0.34 
Kravangh* 
          
  2-12 years 10 (50) 10 (50) 8464  (51.9) 7838  (48.1) 1.18 1.28 
  13-18 years 8 (42.1) 11 (57.9) 5349  (51.9) 4958  (48.1) 1.50 2.22 
  19-30 years 11 (73.3) 4 (26.7) 6134  (49.4) 6286  (50.6) 1.79 0.64 
  31-50 years 2 (33.3) 4 (66.7) 5510  (47.5) 6081  (52.5) 0.36 0.66 
  51 and older 2 (50) 2 (50) 2467  (40.5) 3627  (59.5) 0.81 0.55 
Sampov Meas 
          
  2-12 years 1 (50) 1 (50) 6705  (51) 6434  (49) 0.15 0.16 
  13-18 years 2 (100) - 5347  (50.5) 5247  (49.5) 0.37 0.00 
  19-30 years 13 (81.3) 3 (18.8) 6516  (49.1) 6765  (50.9) 2.00 0.44 
  31-50 years 3 (75) 1 (25) 5515  (46.2) 6410  (53.8) 0.54 0.16 
Veal Vang* 
          
  2-12 years 18 (51.4) 17 (48.6) 1860  (51.8) 1729  (48.2) 9.68 9.83 
  13-18 years 2 (25) 6 (75) 1083  (53.4) 945    (46.6) 5.54 6.35 
  19-30 years 11 (61.1) 7 (38.9) 1438  (54.2) 1215  (45.8) 7.65 5.76 
  31-50 years 5 (45.5) 6 (54.5) 1622  (53.7) 1396  (46.3) 3.08 4.30 
  51 and older 1 (100) - 569    (54.0) 485    (46.0) 1.76 0.00 
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Materials and Methods 
 
1.0 Pursat, Cambodia Collection Study, 2008 
Biological, medical, and demographic information was obtained through 
the Pursat, Cambodia Collection Study, 2008, under the direction of Dr. Rick 
Fairhurst, M.D., Ph.D. at NIH/NIAID.  In a brief summary, inhabitants living in 
Pursat province, in Western Cambodia, were asked to come to the provincial 
medical clinic in the town of Pursat if they were feeling any malaria symptoms, 
i.e. fever, chills, paroxysm, or malaise.  At the clinic, Cambodian healthcare 
providers performed the routine medical examination that included determining 
the patient’s malaria status by finger prick.  A certified microscopic technician 
prepared and analyzed both a thick and thin blood smear, following the universal 
protocol outlined by the World Health Organization (WHO, 2010b).  Patients with 
isolated P. vivax infections were asked to participate in the study and provide 
informed consent if they were ≥ 2 years of age and weren’t found to have any 
further self-reported illness that the researchers deemed would hinder patient 
compliance or confound the data (HIV infection).  Enrolled participants were 
asked to donate one to three Vacutainer tubes of blood to be used for further 
research, including determining parasitemia, parasite DNA extraction and 
sequencing, human blood typing, diagnostic testing, and serum extraction.   
A total of 313 human sera and 108 parasite genomic DNA samples from 
the 2008 malaria season were provided to Dr. John Adams’s laboratory facilities 
16 
 
at the University of South Florida, College of Public Health, Global Health 
Department.  De-identified medical records for the 179 participants’ visits were 
also provided, based on the honest broker agreement between Dr. Rick Fairhurst 
and Dr. John Adams (Appendix A).  Participant visits consisted of the acute 
(enrollment) visit, the convalescent visit (3-5 weeks after the acute visit), and any 
repeat-acute visits (beyond the 5 week convalescent period).  Parasite genomic 
DNA was only provided from the acute visit.   
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2.0 DNA Sequence Analysis  
The 108 genomic DNA samples were sequenced by Dr. John Adams’s lab 
using the DNA sequence company GeneWiz (South Palinfield, NJ).  Briefly, DBP 
region II (DBPII) was isolated from the genomic DNA and amplified via PCR.  At 
least 400ng of each PCR product along with forward and reverse sequencing 
primers was sent to GeneWiz for nucleic acid sequences.  GeneWiz returned the 
nucleic acid sequences available for 81 of the 108 samples.   
Using conserved epitopes found in DBPII-Sal 1, the universal control for 
DBPII sequences, the nucleic acid sequences were translated to amino acid 
sequences and were aligned to five the DBPII test variants (Sal 1, 7.18, O, P, 
and AH).  A clustalW alignment with the PAM protein weight matrix was 
performed in MEGA 5.05 (Tempe, AZ).  The PAM protein weight matrix weighs 
sequences based on how different the amino acid substitutions are from each 
other, i.e. if both amino acids are hydrophobic or polar (Baxevanis & Ouellette, 
1998).  Since DBPII is comprised largely of conserved sites, with few known 
polymorphisms, only amino acid substitutions that result in a true variation to 
DBP were desired. 
A phylogenetic tree was constructed in MEGA 5.05 based on the results 
from the clustalW alignment.  The tree was constructed using the neighbor-
joining statistical method, the bootstrap phylogeny test with 1000 replicates, the 
Dayhoff model for amino acid substitution, and complete deletion of missing data 
and gaps.  The phylogenetic tree also produced a table of evolutionary distances, 
18 
 
which expresses the sequence distance on the tree as a scalar value (Baxevanis 
& Ouellette, 1998).  
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3.0 ELISA 
A total of 313 serum samples were provided to Dr. Adam’s lab from the 
Pursat, Cambodia Collection Study; including 179 acute sera, 79 convalescent 
sera, and 55 repeat acute sera.  ELISAs were used to determine each samples 
antibody binding affinity to multiple DBPII variants.  Five recombinant DBPII 
(rDBPII) variants, produced in Dr. Adams’s lab and used in previous studies 
pertaining to Papa New Guinea, were selected for serological testing because 
they were representative of variant DBP strains found in various geographic 
regions around the world, including Southeast Asia, South America, Western 
Africa, and the Pacific Islands (Cole-Tobian et al., 2009; unpublished data).  DNA 
from variant strains was used to produce the pure rDBPII to act as the antigen 
used in the stationary phase for ELISAs.   
3.1 General ELISA Protocol. A direct ELISA method was used to 
investigate the antibody binding affinity for all Pursat, Cambodia sera.  Direct 
ELISAs include four main components; the antigen, the primary, antigen-specific 
antibody, the secondary antibody specific for the type of primary antibody, and 
the antibody substrate (Crowther, 2000). During opimization, Immulon 96-well 
plates (Thermo-Scientific) were coated with 50µl of a 2µg/ml concentration of 
rDBPII-Sal 1 and incubated overnight at 4oC.  The plate was washed with a wash 
buffer (PBS/0.05% Tween 20) three times.  The plates were blocked with 100µl 
of blocking buffer (5% nonfat milk/PBS/0.05% Tween 20) at room temperature on 
a plate shaker for 2 hours.  The plates were washed with wash buffer three times 
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and 50µl of the primary antibodies was added to the wells; each was diluted 
differently based on the experiment.  The primary antibody incubated at room 
temperature on a plate shaker for 2 hours.  The plates were washed with the 
wash buffer three times and 50µl of the secondary antibody was added to each 
well at a 0.5µg/ml concentration.  The secondary antibody was a goat anti-human 
phosphotase antibody that binds to human made antibodies.  The secondary 
antibody incubated at room temperature for 1.5 hours on a plate shaker.  The 
plates were washed with the wash buffer three times and 50µl of substrate 
solution was added to each well.  The substrate used was a phosphotase 
substrate system that binds specifically to the phosphotase of the secondary 
antibody.  The substrate changes color relative to the amount of secondary 
antibody bound to the plate.  Since the substrate is photosensitive, plates were 
wrapped in aluminum foil and placed in a dark cabinet for 20 minutes.  The 
degree of color change was measured using a spectrophotometer and optical 
density (OD) values were recorded.   
3.2 ELISA Control Selection.  Prior to testing experimental sera a positive 
human serum control was needed as a standard curve, used for normalizing the 
antibody response to multiple samples, and a negative human serum control was 
needed as a quality control, to prove any binding observed during the ELISAs 
wasn’t due to nonspecific binding of the secondary antibody to the antigen and to 
determine the cut-off value for the experimental sera.  High titer human sera from 
a previous study in Papua New Guinea were tested individually in ELISAs and 
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pooled as the standard curve (King et al., 2008).  The positive pooled serum was 
titrated using doubling dilutions and half-log dilutions, starting at 1:10, to 
determine which dilution pattern produced the most complete dose-response 
curve.  The standard curve, using half-log dilutions, was performed on each plate 
coated with rDBPII antigen.  Twelve North American, malaria naïve negative 
control serum were tested at a 1:100 dilution to determine reactivity and those 
with an OD value below 0.055 were pooled for the negative control.  The 95% 
confidence interval of the t-distribution of the individual negative sera OD values 
were used to determine the cut-off value for the experimental sera (Equation 1) 
(Dixon & Massey, 1983; Frey, Di Canzio, & Zurakowski, 1998).   
Equation 1: Cut-off Determination 
    	
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 where n=number of negative sera in the pooled control 
 degrees of freedom=11 
 
 To determine the spectrum of reactivity for the experimental Cambodian 
sera, the first 21 convalescent sera were screened, through ELISA, against the 
standard curve.  It was believed that the convalescent sera would have a higher 
antibody titer than the acute sera, providing an expected maximum range for 
antibody response.  From this screen, the highest, lowest, and middle 
responders were selected to be titrated to visualize the reactivity spectrum.   
Based on these curves the 1:200 dilution was selected because it best described 
the antibody response for all three sera.    
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3.3 Experimental ELISAs.  To test the experimental sera, Immulon 96-well 
plates were coated with 100µl of a 2µg/ml concentration of each rDBPII antigen 
(Sal 1, 7.18, P, O, and AH) and incubated overnight at 4oC.  This was to ensure 
maximum coverage of the wells.  After washing and blocking the plates, they 
were washed as previously stated and 100µl of the primary antibodies of varying 
types were added to the wells (Figure 4).      
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Figure 4: ELISA Plate Map.  The standard curve (green) is the pooled positive serum was diluted 
at 1:1000, 1:3162, 1:10,000, and 1:31622.  The pooled negative control serum (blue) was diluted 
at 1:1000.  The protein control (blue) was where antigen was coated on the plate, but was not 
probed with a primary antibody.  The PBS coated wells (red) were probed with the same 
experimental sera to determine the amount of non-specific binding occurs due to the 
experimental antibody.  All Cambodian experimental sera (denoted as “sample”) were diluted at a 
1:200 dilution. 
  
1 2 PBS 4 5 6 7 8 9 10 11 12
A SC-1000 SC-1000 SC-1000 Sample 3 Sample 5 Sample 7 Sample 9 Sample 11 Sample  13 Sample 15 Sample 17 Sample 19
B SC-3162 SC-3162 SC-3162 Sample 3 Sample 5 Sample 7 Sample 9 Sample 11 Sample  13 Sample 15 Sample 17 Sample 19
C SC-10k SC-10k SC-10k Sample 3 Sample 5 Sample 7 Sample 9 Sample 11 Sample  13 Sample 15 Sample 17 Sample 19
D SC-31622 SC-31622 SC-61322 Sample 3 Sample 5 Sample 7 Sample 9 Sample 11 Sample  13 Sample 15 Sample 17 Sample 19
E neg-1000 neg-1000 neg 1000 Sample 4 Sample 6 Sample 8 Sampe 10 Sample 12 Sample 14 Sample 16 Sample 18 Sample 20
F Sample 1 Sample 2 Protein Sample 4 Sample 6 Sample 8 Sampe 10 Sample 12 Sample 14 Sample 16 Sample 18 Sample 20
G Sample 1 Sample 2 Sample 1 Sample 4 Sample 6 Sample 8 Sampe 10 Sample 12 Sample 14 Sample 16 Sample 18 Sample 20
H Sample 1 Sample 2 Sample 2 Sample 4 Sample 6 Sample 8 Sampe 10 Sample 12 Sample 14 Sample 16 Sample 18 Sample 20
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The experimental sera, diluted at 1:200 were added to the plate in triplicate.  The 
standard curve was diluted using half-log dilutions, starting with a 1:1000 dilution, 
and added to the wells in duplicate, representing the log phase of the standard 
curve.  The pooled negative control serum was added in duplicate to the antigen 
coated wells to show that antibodies not produced to DBPII will not bind to the 
rDBPII.  All types of primary antibodies were also added to the PBS wells, which 
were coated with PBS and not the test antigen.  These wells act as a serum 
control to determine the amount of non-specific binding that occurs due to the 
antibody.  There was one well without any primary antibody added to act as the 
antigen control, used to determine if there was any non-specific binding was due 
to the rDBPII.  The primary antibody incubated at room temperature on a plate 
shaker for 2 hours.  The plates were washed as previously stated and the goat 
anti-human phosphotase secondary antibody was added to each well at a 
0.5µg/ml concentration.  The secondary antibody incubated at room temperature 
for 1.5 hours on a plate shaker.  The plates were washed as before and the 
phosphotase substrate solution was added to each well.  Plates were wrapped in 
aluminum foil and placed in a dark cabinet for 20 minutes.  The degree of color 
change was measured using a spectrophotometer and OD values were 
recorded.   
3.4 ELISA Calculations.  Each primary antibody was tested against each 
rDBPII antigen, in triplicate, and a PBS coated well.  The OD value from each 
serum control well was subtracted from its corresponding experimental well, 
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removing the effect of any background, non-specific binding due to the serum.  
All experimental OD values below the cut-off of 0.055 were considered non-
responders to the rDBPII antigen.  The triplicate values, minus the background, 
were averaged and normalized compare to the standard curve value with an OD 
value closest to 1.0 (Equation 2). 
 
Equation 2: ELISA normalization    	 !"#$%&' 
 	('&)#) 
   
 
Sera with ELISA units within the upper ELISA unit quartile for each type of 
experimental sera (acute, convalescent, and acute-repeat), were considered high 
responders to the specific rDBPII antigen.  Those sera above the cut-off OD 
value, but within the lower ELISA unit quartile for each experimental sera type 
was classified as a low responder to the specific rDBPII antigen.  Those sera 
between the upper and lower ELISA unit quartiles were considered mid 
responders to the specific rDBPII antigen.   
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4.0 Analysis of Medical and Laboratory Data 
 Medical data from the Pursat, Cambodia collection Study, 2008 was 
reviewed for duplicate data.  “Episode” and “follow_up” variables account for 
convalescent and repeat-acute sera values (Table 2).  Medical variables (“fever”, 
“headache”, “body ache”, “malaise”, “vomiting”, “paroxysm”, “shivering”, “chills”, 
and “sweating” ) were converted from character variables to binary coding (0=no, 
1=yes).  Demographic variables (“gender”, “location”, and “residence”) were 
converted from character variables to numeric variables.  When the numeric 
variable “temperature” was cross-referenced with the variable “fever” a large 
discrepancy was found; patients who answered “yes” to the question “Do you 
have a fever?” did not necessarily present a temperature during the medical 
examination.  A new variable was created characterize a fever based on the 
numeric “temperature” variable and not based on the self-reported fever variable.  
This inaccuracy led to a fear that all self-reported variables are untrustworthy and 
not validated.  There may have been an issue with the way the questions were 
worded.  Because of this, they were excluded from analysis.  Continuous ELISA 
units and categorical ELISA values (high, mid, or low responder) for each sample 
were added to the Pursat, Cambodia Collection study data set.  Also, Pursat 
census data (gender, age, and district) from 2008 was added to a copy of the 
Pursat, Cambodia Collection study data set.    
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Table 2: Data Dictionary for Pursat, Cambodia Collection Study, 2008.   
 
The data dictionary was used to convert the character variables into numeric variables.  Variables 
used to make the data dictionary come from the original Pursat, Cambodia Collection Study.   
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5.0 Research Question 1:  Which Variant of the DBL Domain is Responsible 
for the Largest Burden of Disease in the Pursat Study? 
 The surrogate outcome variable used to measure the burden of disease in 
Pursat, Cambodia was antibody binding affinity to the variant rDBPII antigens.  It 
has been shown in previous research that variants of DBPII present differing 
binding affinities during serological tests (Ceravolo et al., 2009; Chootong et al., 
2010; King et al., 2008).  The main exposure variable to represent the variation of 
the DBL domain was measured by the evolutionary distance the amino acid 
sequence was from the DBPII control sequence, DBPII-Sal 1. Since it wasn’t 
possible do determine if participants were infected simultaneously with multiple 
variants of DBPII and because parasite DNA wasn’t available for all sera, the 
ELISAs could also be used to determine if the antibodies produced were specific 
to one strain or multiple strains.   
5.1 Logistic Regression Procedures.  Ordinal logistic regression was the 
preferred method to determine the relationship between the evolutionary 
distances each from DBPII-Sal 1 and antibody binding affinity because it could 
be used to determine how the binding affinity affected the odds ratio.  This would 
provide information about whether the dominant antibodies were binding to a 
conserved epitope of DBPII or a polymorphic epitope.  Since extreme antibody 
affinities provide better information about the infecting parasite, mid responders 
were chosen as the control group and the non, low, and high responders were 
coded as the experimental groups, coded 1-3 respectfully.    
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5.1.1 Ordinal logistic regression.   The ordinal regression was used to 
determine the effect the DBPII variant had on the binding affinity of anti-sera to 
rDBPII variants.  The outcome variable was categorical and compared the 
general population to the extremes.  The reference group was the mid 
responders because people infected with P. vivax should present an average 
antibody response to a variant.  The extreme binding affinities were of 
importance because these participants may be exhibiting a more strain-specific 
immune response related to the DBPII variant of their infection.      
The assumption of parallel regression was test prior to performing the 
ordinal regression, also known as the proportional odds assumption, with the test 
score chi-square.  According to the proportional odds assumption, the slopes of 
the individual outcome levels must be parallel, or proportional, to each other.  
This means that the main exposure variable has to have a similar effect on each 
outcome variable level (Brant, 1990; O'Connell, 2000).  Since they were analyzed 
separately, the test score chi-square had to be done for each rDBPII antigen.  
This assumption was satisfied for rDBPII-AH only.  Therefore, the ordinal 
regression could only be performed on the ELISA results for rDBPII-AH.   
Since the antibody binding affinities are expressed in an ordinal 
relationship, the ordinal regression was the first choice to provide the odds ratios 
for the relationship between the evolutionary distance from DBPII-Sal 1 and the 
binding affinity to each antigen.  The ordinal logistic regression (Equation 3) 
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determines the effect the exposure, evolutionary distance, has on the increased 
ordinal levels of the outcome, antibody binding affinity (O'Connell, 2000). 
Equation 3: Ordinal Logistic Regression 
ln,-./  01 23,/4  ln 5 3,/1  3,/6 
Where the probability of antibody binding is expressed by: 
3,/  7289:'$:&#; )$<'&=,!/41  7289:'$:&#; )$<'&=,!/4 
The advantage of using this method is that the cumulative odds ratio can be 
generated for the data, meaning that the odds of one binding affinity level or a 
combination of multiple binding affinity levels are all considered at the same time.  
The cumulative odds gives more information about the effect evolutionary 
distance has on the increasing binding affinity levels as opposed to the looking at 
the regression of these levels separately.  This method could only be used on the 
antibody response to rDBPII-AH. 
5.1.2 Nominal logistic regression.  The nominal regression was used for 
the remaining rDBPII antigens.  This generalized logit model does account for a 
multilevel antibody response and does not have to satisfy the proportional odds 
assumption; however it is unable to produce a cumulative odds ratio because the 
levels are not taken in order.  As opposed to considering binding affinity as it 
increases, the nominal regression considers each binding affinity level in no 
particular order (Equation 4) (Hedeker, 2003).   
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 Equation 4: Nominal Logistic Regression: Generalized Logit Model 
 
01 3>3#  ?>  @>,7A0BCD EB7/ 
 
Where 3>= an experimental antibody binding level 
 3#= the control antibody binding level (mid-responders) 
With this method it is very important to pre-determine the control values (mid-
responders) and to pay close attention to the order of the additional outcomes 
(non-responder, low responder, and high responder).  For both the ordinal and 
nominal regressions there was not enough power to test each level due to low 
sample size, especially the non-responder level, to support the methods; 
therefore the traditional logistic regression was considered.   
 5.1.3 Logistic regression.  The multiple antibody levels were removed from 
simultaneous consideration and the logistic regression was used to determine 
the separate relationships between on specific level compared to all other levels.  
With this method one level, for example the low responder level, was compared 
to the combination of all other levels (Equation 5); meaning the odds of being a 
low responder compared to the odds of responding any other way.   
 Equation 5: Logistic Regression 
-  1,1  7F,GH9GI,:'$:&#; )$<'&=// 
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However, this didn’t increase the sample size enough to increase the power for 
the analysis.  At this point it was decided that it wasn’t possible to obtain odds 
ratios to describe the relationship between evolutionary distance and antibody 
binding affinity. 
5.2 Generalized Linear Model.   
5.2.1 Fit the generalized linear model. Since categorizing the antibody 
binding affinity for a logistic regression diminished the power for the model, the 
antibody binding affinity and evolutionary distance were taken as continuous 
variables and used in a generalized linear model (GLM).  The GLM allows the 
antibody binding affinity to fit a specified distribution and appropriate link function.  
The link function is used to specify the relationship between the evolutionary 
distance and the binding affinity because the relationship isn’t naturally linear 
(McCullagh & Nelder, 1989).  Since the data follow a more logistic pattern than a 
linear pattern the log link function was used.  The crude model for the 
relationship between the evolutionary distance from DBPII-Sal 1 and the binding 
affinity for each of the rDBPII antigens was used to determine a separate 
distribution which was appropriate for the individual rDBPII antigens.  The 
Pearson chi-square (Equation 6) was used to measure the goodness-fit for each 
model (McCullagh & Nelder, 1989).   
 Equation 6 Pearson Chi-Squared Goodness of Fit 
 
  Where y= is the binding affinity for a specific rDBPII 
Χ2  L ,�� ��	/2��2  
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If the p-value for the Pearson chi-square was less than or equal to 0.05, then the 
distribution was accepted.  As a result, DBPII-Sal 1, 7.18, O, and AH used the 
Inverse Guassian distribution and DBPII-P used the gamma distribution.  The log 
link function was appropriate to use for both distributions (McCullagh & Nelder, 
1989; Nelder & Wedderburn, 1972).    
 5.2.2 Confounding exploration.  Once the valid models were selected, the 
crude and adjusted values were compared.  Possible confounding variables were 
explored only if they were biologically applicable to the investigation.  
Demographic variables (gender, age, and resident district) were examined first.  
Age was considered as a continuous variable and as a categorical variable.  
Initially the five age groups were 2-12 years, 13-18 years, 19-30 years, 31-50 
years, and 51 years or older.  These groups were chosen based on 
internationally understood age ranges and an attempt to control the frequency in 
each group, except for the oldest group.  Since there wasn’t enough power for 
the numerous groupings for the GLM, the age groups were collapsed into two 
groups, those 18 years or younger and those over the age of 18.  There wasn’t 
enough power for these groups either.  Resident district was originally 
categorized as the six districts (Sampov Meas, Bakan, Krakor, Kandieng, 
Kravagh, and Veal Vang).  There wasn’t enough power for this analysis, so the 
districts were collapsed into two groups, the forest districts (Kravagh and Veal 
Vang) and the non-forest districts (Sampov Meas, Bakan, Krakor, and Kandieng).     
34 
 
 Medical variables (temperature, blood pressure, heart rate, respiratory 
rate, hemoglobin level, parasitemia, blood type and Rh type) were also explored 
for counfounding.  Numeric temperatures were categorized as being feverish, 
37oC and above, and normal, below 37oC.  The heart rate, respiratory rate, and 
blood pressure were for all participants were seen to be within normal 
parameters; therefore, they were not explored as confounding variables.   The 
hemoglobin level variable was explored as a categorical variable.  Those 
participants with a hemoglobin level less than 11g/dL were considered anemic 
and those with a hemoglobin level less than 7g/dL were considered severely 
anemic.  Anemia and severe anemia were categorized as two separate 
variables.  Parasetemia was explored as a continuous variable.  Blood type and 
Rh type were explored as categorical variables.  Also, month of clinic visit and 
participant collection location (clinic or mountain) were also explored for 
confounding.   
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6.0 Research Question 2: Are specific polymorphic alleles responsible for 
the burden of disease? 
 To obtain a better understanding of the distribution of P. vivax variants, it 
is important to not only know how the variants differ, but also to know how those 
differences affect the burden of disease.   The correlation between specific 
polymorphisms and antibody binding affinity, used as a surrogate for burden of 
disease, was explored.  This correlation was to identify antibody responses that 
were strain-specific or strain-transcending and to determine if any specific 
polymorphism was related to the antibody response.   
6.1 Correlation Analysis for Antibody Response.  The first correlation 
analysis was to determine if antibody response levels to the various rDBPII 
antigens were related.  The low and high antibody affinity levels used for the 
ordinal regression were used for the separate correlations.  The sample size for 
the non-responders was too low and was not considered in this analysis.  Again, 
the mid-responders constituted the general population.  The dataset was 
condensed to only include responses for high binding affinity to any rDBPII 
antigen tested.  Since the antibody binding affinities failed the Anderson-Darling 
test for normality, the Spearman rank correlation (Equation 7) was used to 
determine the correlation because it is a non-parametric test.   
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Equation 7: Spearman Rank Correlation 
C<  1  6 L EOP   
Where d=rank difference between antibody binding affinity measurements 
 n=the number of antibody binding affinity measurements 
This analysis helped to determine if the antibody response was high to one DBPII 
variant, would it be expected to be high to another DBPII variant.   The same 
process was done for low binding affinity. 
 6.2 Correlation Analysis for a Specific Amino Acid Polymorphism.  Further 
analysis was performed to determine if the specificity of the antibody response 
could be attributed to a specific polymorphic amino acid.  Using the DBPII-Sal 1 
sequence as the control sequence, the polymorphisms in the Cambodian 
genomic DNA sequences were given binary coding (0=same amino acid as 
DBPII-Sal 1, 1=different amino acid than DBPII-Sal 1).  The point-biserial 
(Equation 8) correlation was used to determine if antibody binding affinity was 
correlated to specific amino acid substitutions.   
 Equation 8: Point-Biserial Correlation 
C"Q  ∆-& ST  UO  
 Where  Y= the score mean for each rDBPII antigen 
  s = standard deviation of the sample 
  n=the sample size for each rDBPII antigen 
This analysis explored the correlation between a dichotomous variable, 
specific alleles, and a continuous variable, antibody binding affinity.  To adjust for 
37 
 
possible confounding variables, a partial point-biserial correlation was performed.  
Demographic variables (gender, age, and resident district) were tested first.  Age 
was explored as a categorical variable in two groups, 18 years and below and 
above 18 years.  Resident district was also explored as a categorical variable in 
two groups, forest districts and non-forest districts.  The same medical variables 
tested in the GLM method were also tested for confounding.    
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Results 
 
1.0 DNA Sequencing and Evolutionary Distances 
Parasite genomic DNA was aligned and sequenced using MEGA 5.05.  A 
phylogenetic tree was constructed the using neighbor-joining statistical method.  
The bootstrap phylogeny test with 1000 replications and the Dayhoff method was 
used for amino acid substitution.  Of the 89 sequences, 29 were in the same 
clade as DBPII-Sal 1(Figure 5).  DBPII-O also had a high number of similarities 
with 15 Cambodian samples in its clade.  DBPII-AH had the lowest number of 
similarities, with only one Cambodian sample in the same clade.   
Evolutionary distance was used to measure the degree of polymorphic 
changes among the Cambodian parasite DNA.  Because there were very few 
polymorphic variations within the 222 amino acid alignment, the evolutionary 
distances from DBPII-Sal 1 were very small (Table 4).  According to the 
evolutionary distance, 24, approximately 30%, acute Cambodian samples were 
the same as the DBPII-Sal 1, with an evolutionary distance of 0, while only 1 
Cambodian sample had an evolutionary distance of 0.31, the farthest distance 
from DBPII-Sal 1.    
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Figure 5: Cambodian Acute Parasite Phylogenetic Tree.  Parasite genomic DNA from 81 acute 
Cambodian samples were amplified through PCR and sequenced by GeneWiz.  Protein 
sequences were aligned using a ClustalW alignment with a PAM protein matrix.   A phylogentic 
tree comparing the Cambodian samples to the five test variants constructed using the neighbor-
joining statistical method, bootstrap phylogeny test, with the Dayhoff model of amino acid 
substitution.  The majority of Cambodian parasite DNA is similar to the control DNA, DBPII-Sal 1. 
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Table 3: The Frequency of Evolutionary Distances from DBPII-Sal 1. 
Evolutionary 
Distance 
from 
DBPII-Sal 1 Frequency Percentage 
0 24 30.38 
0.018 5 6.33 
0.0364 4 5.06 
0.0551 13 16.46 
0.0741 6 7.59 
0.0935 2 2.53 
0.1133 8 10.13 
0.1135 1 1.27 
0.1335 13 16.46 
0.1542 2 2.53 
0.3118 1 1.27 
 
The evolutionary distances from DBPII-Sal 1 were calculated based on the phylogenetic tree.  
Because the same were so similar to each other, all samples fit within 11 distances. The 
frequency was based on the number Cambodian samples with that distance and the percentage 
is based on the 81 samples.   
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2.0 ELISA Analysis 
2.1 ELISA Optimization.  Prior to the serological analysis of the human 
sera from 179 Cambodian study participants a pooled positive standard human 
sera was selected and a pooled human sera naïve to malaria was screened to 
optimize the protocol.  Pooled human serum from Papua New Guinea with high 
antibody titers for DBPII was used as the positive standard curve.  The standard 
curve was titrated using both doubling dilutions and half-log dilutions (Figure 6).  
The half-log dilutions provided all the properties of the reaction curve; therefore, 
was the dilution scheme adopted for the experimental ELISAs.  The standard 
curve was performed on each rDBPII variant to provide a reaction pattern for 
each antigen (Figure 7).    The pooled positive serum was found to react similarly 
to each recombinant protein. 
The DBPII-Sal 1 standard curve was compared to three randomly selected 
experimental Cambodian sera (Figure 8).  The reactivity of the pooled positive 
serum was aligned with the reactivity of the selected Cambodian sera.  Based on 
the aligned values, a 1:200 dilution was selected to test all experimental sera.   
Individual North American malaria naïve sera were screened against 
DBPII-Sal 1 and those sera with an OD value below 0.055 were pooled for the 
negative control (Figure 9).  North American samples 401, 402, 403, 405, 410, 
411, 412, 413, 414, 416, and 417 were chosen for the pooled negative control 
sera.  The negative control serum was placed on each experimental plate at a 
1:1000 dilution.     
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Figure 6: Standard Curve Dilutions.   Pooled positive serum from PNG were titrated using two 
dilution patterns to produce the standard curve.   Error bars represent the one standard deviation 
away from the mean OD value of triplicate wells at each dilution.    
a.) 
b.) 
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Figure 7: Standard Curve for rDBPII Antigens.  The PNG pooled positive serum was diluted, half-
log dilutions, against the five test rDBPII antigens.  The log phase of each dilution curve was fit to 
a line to locate a dilution factor that can be used to normalize all experimental values.  
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Figure 8: Selection of Experimental and Standard Dilutions.  a.) The standard curve was titrated 
using half-log dilutions.  Several Cambodian convalescent field sera were screened against the 
pooled positive serum to compare reactivity.  b.) The highest, lowest, and a middle responder 
were chosen to be completely titrated.  The standard curve was found to have a higher binding 
affinity than the experimental sera.  The lines represent  the corollary antibody dilutions 
considered for both the standard curve and the experimental sera.    
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Figure 9: Pooled Negative Control Sera Selection.  Negative control sera were screened from 
multiple North American malaria naïve individuals to decide which to pool for the negative control 
and use to calculate the cut-off point.    
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 2.2 Experimental ELISAs for All Recombinant Proteins.  ELISAs were 
performed for each rDBPII antigen on each type of sera (acute, convalescent, 
and repeat-acute).   High responders for the experimental sera were identified as 
those sera in the upper quartile range of each type (Figures 10-12).  Based on 
the high responders, strain-specific and strain-transcending sera were identified.  
Strain-specific sera were identified as those sera that were highly reactive to no 
more than two rDBPII antigens.  Strain-transcending sera were identified as 
those that reacted highly to four or more of the rDBPII antigens.  The 
convalescent and repeat-acute sera produced more strain-specific sera than the 
acute sera; however, the reactivity of these sera was far lower than that of the 
acute sera.  This reactivity pattern was different than expected.  Also, due to 
sample restraint, there were few opportunities for temporal comparisons of an 
individual’s sera.  For this reason, the convalescent sera and the repeat-acute 
sera were not considered for further analysis.   
 Strain-specificity suggests the serum bind to an epitope not found in the 
other DBPII antigens.  This allows sera to be mapped to certain polymorphic 
alleles.  It is important to note that DBPII-AH produced the most strain-specific 
reactions to the acute Cambodian sera, suggesting those sera are reacting to an 
epitope not found in the other DBPII antigens.  Since the only difference between 
DBPII-7.18 and DBPII-AH is the K371E polymorphism, it is hypothesized that the 
sera are reacting to an epitope including this polymorphism.   
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 Strain-transcending sera are hypothesized to bind to an epitope found in 
multiple DBPII antigens, thought to be conserved epitopes.  It is important to note 
that only two acute sera are highly reactive to all five rDBPII antigens; therefore 
it’s hypothesized that these sera bind to a conserved epitope found on all DBPII 
variants.  None of the convalescent sera were found to have a high binding 
response to four or more DBPII variants, meaning that the convalescent sera 
were found to be more strain specific.  Only one or the repeat-acute responders 
was found to have a strain-transcending antibody response and that individual 
didn’t exhibit a high antibody binding affinity to the variants on the acute visit.   
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 Figure 10: High Acute Responder Comparison.  High responder sera  during the acute visit was 
identified as those sera with an antibody affinity within the upper quartile.  Approximately half of 
high acute responders demonstrate a strain-specific immune response to only one DBPII variant, 
with DBPII-AH exhibiting the most strain-specificity.  This sera demonstrating a high response to 
DBPII_AH are not as likely to exhibit a high immune response to  DBPII-7.18.  
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Figure 11: High Convalescent Responder Comparison.  High responder sera was identified as 
those sera with an antibody affinity within the upper quartile of  the convalescent sera.  The 
convalescent sera  exhibits less of a strain-transcending immune response, which only four sera 
binding to three variants.   
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Figure 12: High Acute-Repeat Responder Comparison.  High responder sera was identified as 
those sera with an antibody affinity within the upper quartile of each the repeat-acute sera.  The 
repeat acute sera exhibit less strain-transcending immune responses, with only three sera 
binding to three or more variants.   
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3.0 Logistic Regression Analysis 
 3.1 Ordinal and Nominal Regression Analysis.  The antibody binding 
affinity was categorized into four levels, as described in the methods.  Because 
the antibody responses to DBPII-AH were the only responses that satisfied the 
proportional odds assumption, the ordinal logistic regression was only used on 
that variant.  The nominal logistic regression, with the mid responders as the 
reference group, would provide odds ratios to compare between each group as 
opposed to the cumulative odds ratios the ordinal logistic regression would 
provide.   
 According to the results of both the ordinal and nominal regressions, there 
is not enough power to determine an appropriate odds ratio (Table 4).  Many of 
the odds ratios provided were too large to calculate (>999.99) or too small to 
calculate (<0.001).  Moreover, the confidence intervals, although significant, were 
infinitely large and unable to be calculated.  The lack of power was either due to 
a low sample size of the reference group for each DBPII variant or due to a low 
sample size in each categorical level.  It wasn’t clear from this analysis which 
situation would have caused these odds ratios.      
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Table 4: Results of the Ordinal and Nominal Regression 
 
Only DBPI-AH (red) satisfied the proportional odds assumption, so it was the only antigen to 
undergo ordinal regression.  The remaining antigens were able to undergo nominal logistic 
regression, which doesn’t have to satisfy the proportional odds assumption.   The small sample 
size for each antibody affinity level didn’t provide the amount of power needed for this type of 
analysis.    
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 3.2 Simple Logistic Regression Analysis.  A simple logistic regression was 
performed to determine if there was an association between evolutionary 
distance and each separate categorical level of the antibody response.  Antibody 
response at each level was given a binary category, with the reference group 
containing all antibody response levels except the level being tested.  This would 
increase the sample size of the reference group and thereby increasing the 
power of the analysis.  The odds ratios produced wouldn’t be cumulative, but it 
would still be possible to compare odds ratios between groups.  
 Although the simple odds ratio does increase the sample size of the 
reference group, this was not enough to increase the power for this analysis 
(Table 5).  That means the sample size in each level was too low to produce 
adequate odds ratios.  Since I feel it is very important to know the differences 
between low and high responders, I didn’t feel it was appropriate to combine 
antibody binding levels to increase the sample size of the experimental groups.  
Also, since the sample size within antibody levels was too small, there was no 
need to adjust for confounding.  The odds ratios couldn’t be interpreted in their 
crude or adjusted forms.      
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Table 5: Results of the Logistic Regression   
 
A logistic regression, using binary coding for each antibody response level, was used to show the 
relationship between the evolutionary distance from Sal 1 and the antibody binding affinity. Each 
response variable level is coded as 1=desired level and 0=all other levels.  The crude regression 
was revealed that the sample size was still too small and there wasn’t enough power to perform 
this analysis.    
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4.0 GLM Analysis 
 Since the sample size within each antibody binding level was too small, 
the antibody binding affinity was taken as a continuous variable to increase the 
power of the analysis.  A generalized linear model (GLM) was used to explore 
the relationship between the continuous evolutionary distance from DBPII-Sal 1 
and the continuous antibody binding affinity.  The GLM used a log link function, 
to explore the data as a log function along an Inverse Gaussian distribution.  This 
means the parameters determined by the equation are based on a log function.  
Using the GLM parameters produced the percent change for each DBPII was 
determined.   
 The crude GLM parameters, those showing the relationship between the 
evolutionary distance from DBPII-Sal 1 and the antibody binding affinity to the 
different variants, were much higher than those adjusted for parasitemia (Table 
5).  The crude GLM parameter for DBPII-Sal 1 was 8.54 and dropped to -0.0005 
(-0.0008 - -0.0002) when adjusted for parasitemia.  The adjusted percent change 
was -0.05.  This means as the evolutionary distance from Sal 1 increase the 
antibody binding response to DBPII-Sal 1 undergoes a slight percent drop, when 
controlled for increasing parasitemia.  In other words, sera with antibodies to a 
variant similar to DBPII-Sal 1 will bind more strongly to DBPII-Sal 1.  The other 
parameters weren’t significant when adjusted for parasitemia.  Other 
demographic confounding variables were explored, but none of them changed 
the crude GLM parameter.      
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Table 6: Results of the GLM 
 
Using both the evolutionary distance and the antibody titer as continuous variables, the 
generalized linear model could be used to describe their relationship.  The crude parameter 
coefficient for the evolutionary distance is compared to the adjusted coefficient, adjusted for 
parasitemia.  DBPII-Sal 1 became statistically relevant once adjusted for parasitemia.   
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5.0 Serologic Response Correlation.  
 The first step in exploring whether a specific polymorphic site is 
responsible for the observed antibody responses is to determine if the antibody 
responses for the different variants are related to each other.  The Spearmen 
Rank correlation was used to test the correlation of the antibody response levels 
between variants.  Among high responders, there is a correlation in antibody 
response between variants DBPII-Sal 1, 7.18, O, and P.  This means that sera 
responding highly to DBPII-Sal 1 are also likely to respond highly to DBPII-7.18, 
O, and P.  There is a strong correlation between being a high antibody responder 
to DBPII-P and a high responder to DBPII-7.18 or O (r=0.88).  The correlations 
between DBPII-Sal 1 and the 7.18, O, and P are not as strong.  High response to 
DBPII-AH is not correlated to any other tested variant.  This shows that DBPII-AH 
produced a more strain-specific immune response compared to the tested 
variants.  This pattern was not obtained for the correlation between low 
responders to the variants (Table 6).  There is a strong correlation between being 
a low responder to one variant and a low responder to other variants.   
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Table 7: Correlation of High DBPII Responders 
 
A Spearman rank correlation was used to show the relationship between high responders to 
multiple DBPII variants.  The correlation coefficient (r) and the p-value suggest that only sera that 
bind to DBPII-AH tend to be more strain specific.  
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Table 8: Correlation of Low DBPII Responders 
 
A Spearman rank correlation was used to show the relationship between low responders to 
multiple DBPII variants.  The correlation coefficient (r) and the p-value suggest the experimental 
sera respond equally low to all the test rDBPII antigens.  
60 
 
6.0  Antibody Binding Affinity Correlated to Specific Amino Acids 
 The polymorphic amino acid sites chosen have been shown to inhibit the 
parasite binding to the erythrocyte.  In addition, the amino acid at site 371 is the 
only amino acid change difference between DBPII-AH and 7.18, a glutamic acid 
substituted for the lysine, and is thought to be involved with the immune 
response difference between the two variants.  The scope of the polymorphisms 
was compared at these sites (Figure 13).  The prominent amino acid sequences 
were listed and color-coded to show their position on the DBPII homology 
structure.  All the selected polymorphic alleles were shown on the surface, 
except the 437 site, which is partially hidden.     
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Figure 13: Allele Variations and Locations.  The five test DBPII variant sequences were aligned 
with the prominent genomic parasite DNA of the acute Cambodian visits, each numbered 
sequence appeared at least once in Cambodia.  Important amino acid substitutions, possibly 
used to evade the immune system, are highlighted in the table and the molecular homology 
model of DBPII.  The K371E substitution (green) is the only amino acid difference between 
DBPII-7.18 and DBPII-AH and is responsible for the different binding affinity patterns between the 
variants.  The amino acids at 384-386 (blue) are considered to be the most polymorphic in DBPII 
and are thought to be located near the erythrocyte binding site.  The amino acids at 417, 424, and 
437 (red) are thought to be important in erythrocyte binding inhibition. The yellow highlighted 
region is also a common polymorphism in region II.   
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The point-biserial correlation was used to determine the correlation 
between specific amino acid sites and antibody binding affinity to the test 
variants. The amino acid sequence for DBPII-Sal 1 was used as the control 
sequence.  Each polymorphic site was correlated to the continuous antibody 
binding affinity to each of the test variants.  The crude point-biserial coefficient 
was compared to the adjusted coefficient, adjusted for location of the patient’s 
collection (the road or the clinic) (Tables 7 and 8).   
Despite the amino acid difference between DBPII-Sal 1 and AH, there was 
no correlation between the 371 amino acid and antibody binding affinity.  There 
was also no correlation between the 371 amino acid site and DBPII-7.18, which 
has the same glutamic acid as Sal 1.  The correlation does reaffirm the 384-386 
amino acid sites are loosely correlated to antibody binding affinity.  This loose 
correlation was also seen at site 390 and 437.  It is unclear which specific amino 
acid is responsible for the immune response.    
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Table 9: Results of Amino Acid Correlation 
 
Amino acids that have been shown to be important for antibody binding and inhibitions of 
erythrocyte binding were examined to identify a correlation between the amino acid substitution 
and the antibody binding affinity to the variant.  The substitution of selected amino acids, based 
on the control sequence of DBPII-Sal 1, were coded using binary code (0=the same amino acid 
as DBPII-Sal 1, 1= a different amino acid than DBPII-Sal 1).  A point biserial correlation was used 
to assess the relationship between the binary amino acid and the continuous antibody binding 
affinity.  The point biserial correlation coefficient (ρpb) was used to determine the direction and 
strength of the correlation.  A partial correlation was used to adjust for location.   
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Table 10: Amino Acid Correlation Adjusted for Location 
 
Amino acids that have been shown to be important for antibody binding and inhibitions of 
erythrocyte binding were examined to identify a correlation between the amino acid substitution 
and the antibody binding affinity to the variant.  The substitution of selected amino acids, based 
on the control sequence of DBPII-Sal 1, were coded using binary code (0=the same amino acid 
as DBPII-Sal 1, 1= a different amino acid than DBPII-Sal 1).  A point biserial correlation was used 
to assess the relationship between the binary amino acid and the continuous antibody binding 
affinity.  The point biserial correlation coefficient (ρpb) was used to determine the direction and 
strength of the correlation.  A partial correlation was used to adjust for location.    
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Discussion 
1.0 Antibody Response Over Time. 
The Purst, Cambodia Collection Study was a cross-sectional study 
designed collect active and passive surveillance data about P. vivax infections 
from inhabitants of Pursat Province.  During the study researchers from Dr. Rick 
Fairhurst’s laboratory collected medical and demographic information about 
individuals infected with P. vivax, as well as blood samples to test human and 
parasite characteristics.  The goal of this descriptive study was to characterize 
the serologic response to P. vivax in a seasonally endemic region using human 
sera and parasite genomic. 
Dr. Adams’s laboratory was provided with acute, convalescent, and 
repeat-acute sera and parasite genomic DNA.  Parasite genomic DNA was only 
available for 79 of the 179 acute patient visits.  Therefore, the sample size for 
this descriptive study was 79 participants.  Although it would have been prudent 
to examine the antibody response of study participants from their acute visit 
through their convalescent visit, there were not enough study participants within 
the first 79 patients to return for their convalescent visit.  There was no parasite 
genomic DNA provided for the repeat-acute responders, leaving no method of 
comparing the prominent DBPII variant between visits.  Because of these 
obstacles, immune response over time could not be adequately analyzed.   
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2.0 Association Between DBPII Variants and Antibody Response 
2.1 DBPII Variants.  Variations in DBPII were measured using the 
evolutionary distance from DBPII-Sal 1, the first variant of P. vivax to be 
sequenced.  Since DBPII is a highly conserved protein with limited polymorphic 
sites, the evolutionary distance is used to measure the polymorphic differences 
between the Cambodian parasite isolates and Sal 1.  However, because of the 
highly conserved nature of DBPII, the evolutionary distances were very small 
numbers with little variation.  This very small difference in exposure could’ve 
reduced the power of the analysis because a large sample size is needed to 
detect very small differences.  For future studies it might be constructive to 
transform the evolutionary distance in a meaningful way to analyze a larger 
exposure difference.   
DBPII-Sal was the most prevalent variant to infect the study participants, 
with 30% of parasite isolates having the same amino acid sequence and 6% of 
parasite isolates having a one amino acid difference from DBPII-Sal 1.  None of 
the Cambodian variants or the test variants differed completely from Sal 1, 
although DBPII-P differs from DBPII-Sal 1 in every major polymorphic site except 
the glutamic acid at site 371.  Although it has been shown biologically that one 
amino acid can change an individual’s immune and inhibitory response to P. 
vivax, the one amino acid difference is too small to measure and analyze 
appropriately through logistic regression without a very large sample.   
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2.2 Antibody Binding Affinity.  The Pursat, Cambodia Collection Study 
recruited and enrolled only those individuals with clinical symptoms of malaria.    
Therefore, antibody binding affinity to DBPII variants could be used to measure 
the how much malaria illness is due to a particulate variant in the study 
population.  The degree of illness was, in many ways, self –reported by study 
participants and was found to be unreliable information.  The antibody binding 
affinity was a method of measuring the immune response to a DBPII variant and 
could potentially provide information about the, which DBP epitopes the 
antibodies were binding.   
The antibody response couldn’t be categorized because of the low 
sample size and the minute differences within the exposure variables.  Therefore, 
a continuous antibody response was used to measure the immune response to 
the test variants.  Once adjusted for parasitemia, there was a very small percent 
decrease in the antibody binding affinity to DBPII-Sal 1as the evolutionary 
distance moved further away from DBPII-Sal 1.  This means that as more 
polymorphic amino acids varied from those found in DBPII-Sal 1, the antibody 
binding affinity to DBPII-Sal 1 decreased slightly.  This decrease was to be 
expected because 30% of the Cambodian samples were the same as DBPII-Sal 
1.  No such significant drop was seen in the other DBPII test variants.  One 
possible explanation is that the evolutionary distance was measured from DBPII-
Sal 1 only and not from each individual test variant.  To have a better 
understanding of whether the test variants bind human antibodies similar to the 
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Cambodian variants, it might be useful to analyze this relationship with the 
evolutionary distances from each test variant and not just DBPII-Sal 1.   
2.3 Confounding.  Throughout the analysis it was difficult to identify 
confounding variables.  It was initially thought that age and gender could be to 
potential confounders to the analysis.  Studies in PNG, where malaria is 
endemic, show that very young patients become ill with P. vivax infections and 
produce a long-term immunity as they age (Xainli et al., 2002).  Continuous 
exposure to mosquitoes allows for exposure to multiple P. vivax variants at a 
young age, leading to asymptomatic malaria infections or immunity.  This 
continuous exposure is not always the case in Pursat, Cambodia.  Mosquitoes 
are most prevalent in the forest region of the country, including Veal Vang and 
parts of Kravanh known as the forest fringe.  In addition, mosquitoes are more 
prevalent during the rainy season in the forest.  It is unclear how long the rainy 
season lasts or if malaria infections are persistent year round in the forest.  The 
lack of exposure means that all age levels are vulnerable to malaria infections 
and there is no prospect of age-defined immunity.   
It was also hypothesized that gender may be a confounder because 
malaria in Cambodia can be seen as a work related illness.  Workers from the 
four non-forest districts travel to the forest for mining, agriculture, and other 
occupations. It was initially thought that male workers would enter the forest to 
work and come home with malaria; however, men who have to leave for 
extended periods of time will often take their families with them.  Also, families 
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with children live in the forest and along the forest fringe and are exposure to 
malaria more often.  Neither age nor gender were found as confounders during 
the analysis. 
Parasitemia and location of the patient were the only confounders in the 
study.  Parasitemia was measured in parasite per microliter, meaning the number 
of parasite in a microliter of blood.  This is calculated by counting the number of 
parasite per leucocytes in a thin blood smear.  Parasitemia seemed to mask the 
relationship between the evolutionary distance and antibody binding.  
Parasitemia is not in the casual pathway between the parasite variant and the 
antibody response.  Antibodies will be from regardless of the parasitemia; 
however, a higher parasitemia may provide more epitopes for binding.  It is 
unclear whether parasitemia is unclear whether one variant is more virulent than 
another variant; however, it paraistemia could have been influenced by the most 
predominant variant in Cambodia, DBPII-Sal 1.  As the parasitemia and the 
evolutionary distance from DBPII-Sal increased, the antibody binding decreased. 
The variable “location” pertains to the location of the patient at the time of 
diagnosis, whether along the road in Pursat or at the provincial clinic.  Location 
could have been a source of slight confounding to the point-biserial correlation, 
describing the relationship between specific amino acid changes and antibody 
binding affinity.  Once adjusted for in the partial correlation model, the strength of 
the correlation increased slightly.  The location of the participant could be related 
to the DBPII variant by location.  Individuals collected from the road were 
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probably from parts of Veal Vang and Kravanh, meaning that they may have a 
different duration of exposure than those in the non-forest districts.  The location 
could be connected with antibody binding affinity because people from the forest 
regions may be exposure to more variants, thereby making antibodies to multiple 
variants at a time.  There was only slight masking of the relationship between 
exposure and outcome.   
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3.0 Specific Amino Acids Correlated to Antibody Response 
The point-biserial correlation matrix was used to determine if there was a 
relationship between specific amino acids polymorphisms and antibody binding 
affinity.  This was an effort to statistically map the polymorphic alleles responsible 
for specific antibody responses.  Since the amino acid sequences were mapped 
using DBPII-Sal 1 as a control sequence, all amino acid differences were in 
reference to DBPII-Sal 1.  Although having a high antibody response to DBPII-
AH was not correlated to having a high antibody response to any other variant 
and the K371E amino acid substitution is the only polymorphic difference 
between DBPII-7.18 and AH, this amino acid substitution wasn’t statistically 
correlated to higher antibody response.  It was presumed there would be a 
difference in antibody binding to DBPII-AH correlated to the amino acid 
difference at K371E (DBPII-Sal 1 has the same lysine as DBPII-7.18).  However, 
no such correlation exists.   
 There was a weak to moderate correlation between antibody binding to 
each of the variants and sites 384 and 437. Site 384 is part of the DEK region of 
DBP and is the most polymorphic site in region II.  Also, were many polymorphic 
residues in DBPII are dimorphic, the DEK region is known to have multiple 
polymorphic substitutions, potentially due to high immune pressure on this 
region.  The W437R amino acid substitution, a tryptophan to an arginine 
substitution, has also been shown to be important in blocking inhibitory 
antibodies from binding to the DBP active site.  Although there is no difference in 
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these amino acids between DBPII-7.18 and Ah, there is a difference between 
them and DBPII-Sal 1.  This may account for the low correlation between them. 
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4.0 Further Research 
4.1 Thesis Summary.  This was a preliminary study of the first year of sera 
collection from the P. vivax Collection Study.  The purpose of this study was to 
characterize the immune response against P. vivax malaria infections in a 
seasonally endemic region.  It was hypothesized the immune response to DBPII 
variants in Pursat, Cambodia would follow a strain specific pattern, making it 
possible to determine a particular variant most responsible for clinical illness.  
The main exposure was to a particular DBPII variant and the outcome was the 
antibody response to a wide-array of recombinant DBPII variants, helping to 
determine if antibodies were binding to a polymorphic or conserved epitope.  
Based on the results, variants similar to DBPII-Sal 1 tend to bind more strongly to 
that recombinant protein than to any other recombinant protein.   This would 
imply that a variant very similar to or the same as, DBPII-Sal 1 is responsible for 
the majority of clinical illness in the study.  However, these results are based on 
the evolutionary distance from DBPII-Sal 1.  Further analysis may show that, 
given another control amino acid sequence, another variant could be more 
responsible for clinical illness.  Also, there was no parasite genomic DNA 
provided for the repeat-acute sera to determine if individuals were getting 
reinfected with the same or a different DBPII variant.  Although the data would 
suggest that DBPII-Sal 1 is responsible for the burden of clinical illness, the 
information provided made it difficult to make a decisive determination.   
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It was also believed the polymorphic substitutions could be statistically 
mapped as they correlate to the antibody binding affinity to the five variants.  This 
was aimed at providing researchers a guide when determining which amino acid 
substitution should be focused on to identify inhibitory antibodies.  Amino acid 
differences between DBPII-AH and DBPII-Sal1 were thought to be responsible 
for the strain-specific immune response by DBPII-AH, in particular the K371E 
substitution.  This was not possible to determine since the analysis only provided 
weak correlations.   
4.2  Additional Analysis.  This study was unable to confidently identify the 
DBPII variant responsible for clinical disease nor the polymorphic residue 
responsible the immune response.  Additional studies of the sera from 
subsequent years of the study may provide this information.  More than 79 
participants are needed to make a more definitive characterization about variants 
in Pursat.   
This study also focused on the parasites interactions with the host and little 
on the genetic human host determinants of disease.  As the questioning process 
improves between the Pursat researchers and the patients, it would be 
interesting to explore the antibody response and its connection with th e clinical 
symptoms ofdisease.
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